Original document(6 pages)  中文版
    This invention relates to a Chinese medicinal composition used for treating diabetes and its preparation method. The Chinese medicinal composition comprises Astragalus root extract, medlar powder and chromium nicotinate at a wt. ratio of 500:100:1. The preparation method comprises pulverizing Astragalus root, extracting with water, filtering, concentrating, anddrying; drying medlar, pulverizing, and mixing with Astragalus root extract and chromium nicotinate. The inventive Chinese medicinal composition can effectively reduce blood sugar. The composition can be made into medicine with conventional auxiliary materials for treating diabetes.
Application Number
申请号
200610122920 Application Date
申请日
2006.10.20
Title 名称 Medicine composition for treating diabetes and its preparation
Publication Number
公开号
101015627 Publication Date
公开日
2007.08.15
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K36/815;A61P3/10;A61K31/455
Applicant(s) Name
申请人
Sun Yat-sen University
Address 地址
Inventor(s) Name 发明人 Su Weiwei;Wang Yonggang;Wu Zhong
Attorney & Agent 代理人

  
Naringin used in preparing medicine for curing acute and chronic bronchitis
Method for extracting naringin
Health care food for regulating immunity, antioxidation and its preparing method
'Huajuhong' preparation and its preparing process
Method for extracting quercetin-7-0-rhamnoside
Method for preparing alpha-interferon plasmid DNA-liposome preparation
Method for extracting shaddock ped aglycone from shaddock
Method for constituting finger-print pyrogram of white atracty lodes and its standard finger-print pyrogram
Method for constituting TLC finger-print pyrogram of hypericum-japonicum medicinal herbs and its standard finger-print pyrogram
Application of naringin in preparing medicine for supporting treatment of SARS
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.